Loading...
•
Sep 30, 2020
Cerus Q3 2020 Earnings Report
Cerus reported record third quarter results, driven by growth in U.S. platelet kit sales and EMEA region demand.
Key Takeaways
Cerus Corporation announced record third quarter 2020 results with a total revenue of $29.2 million. The company narrowed its full year product revenue guidance to a range of $89 million to $91 million. The company had cash, cash equivalents, and short-term investments of $135.1 million at September 30, 2020.
Total revenue reached $29.2 million, driven by U.S. platelet kit sales growth and EMEA region demand.
A new technology add-on payment (NTAP) application was submitted for pathogen-reduced cryoprecipitated fibrinogen complex (PR-Cryo).
The first two modules for CE Mark for INTERCEPT red blood cells were submitted.
A five-year contract with the FDA was entered into for developing next-generation compounds.
Cerus
Cerus
Cerus Revenue by Segment
Cerus Revenue by Geographic Location
Revenue by Segment
Product Revenue
CapyFin.comGovernment Contract Revenue
CapyFin.comRevenue by Geographic Location
North America Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
The Company expects 2020 product revenue to be in the range of $89 million to $91 million.
Positive Outlook
- Company expects 2020 product revenue to be in the range of $89 million to $91 million
Challenges Ahead
- potential for additional disruptions to the blood supply this fall and winter
- narrowing our 2020 guidance range due to recent sharp rises in new COVID cases in certain regions, including Europe.